ERCC positive tumour had significantly better disease-free survival (HR 0.7, p = 0.028) than ERCC1 negative tumours. ERCC1 positive tumours has significantly reduced risk of recurrences (HR 0.71, p = 0.021). The 5-year DFS and CSS were better for ERCC1 positive than negative, and were respectively 62% vs 49% and 70% vs 59%. However, there was no important outcomes of adjuvant cisplatin-based chemotherapy by ERCC1 status. The gene discussed is ERCC1; the disease is neoplasm.